Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients

Stefano Sacchi, Samantha Pozzi, Luigi Marcheselli, Alessia Bari, Stefano Luminari, Francesco Angrilli, Francesco Merli, Daniele Vallisa, Luca Baldini, Maura Brugiatelli

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

BACKGROUND. It is unclear whether new treatment modalities have improved the survival of follicular lymphoma patients. Some data show that there has been no improvement in survival in the last 3 decades of the 20th century, whereas the results of recent retrospective studies suggest that evolving therapy has improved the outcome for follicular lymphoma patients. METHODS. To evaluate the impact of evolving therapies for follicular lymphoma, particularly the introduction of rituximab, the overall survival (OS), failure-free survival (FFS), and survival after recurrence (SAR) was analyzed in 438 advanced-stage follicular lymphoma patients enrolled in consecutive Gruppo Italiano Studio Linfomi (GISL) trials between 1988 and 2004. RESULTS. A stepwise improvement in FFS and a significant reduction in the hazard ratio was observed with succeeding studies. Cox regression analysis showed an improvement over time for OS, with a decline in the hazard ratio particularly evident in the group treated with rituximab. Furthermore, the SAR significantly improved in the group of patients treated with chemotherapy + rituximab. CONCLUSIONS. After adjusting for all parameters with an impact on FFS and OS, the results of multivariate analysis suggest that rituximab therapy has a favorable effect on the prognosis of follicular lymphoma. The data show that FFS and OS have significantly improved in advanced-stage follicular lymphoma patients treated on GISL protocols during the last 18 years. These improvements are related to evolving front-line and salvage therapies, particularly the introduction of rituximab in combination with chemotherapy.

Original languageEnglish
Pages (from-to)2077-2082
Number of pages6
JournalCancer
Volume109
Issue number10
DOIs
Publication statusPublished - May 15 2007

Fingerprint

Salvage Therapy
Follicular Lymphoma
Survival
Rituximab
Recurrence
Therapeutics
Combination Drug Therapy
Multivariate Analysis
Retrospective Studies

Keywords

  • Chemotherapy
  • Follicular lymphoma
  • Non-Hodgkin lymphoma
  • Rituximab
  • Treatment outcome

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Sacchi, S., Pozzi, S., Marcheselli, L., Bari, A., Luminari, S., Angrilli, F., ... Brugiatelli, M. (2007). Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients. Cancer, 109(10), 2077-2082. https://doi.org/10.1002/cncr.22649

Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients. / Sacchi, Stefano; Pozzi, Samantha; Marcheselli, Luigi; Bari, Alessia; Luminari, Stefano; Angrilli, Francesco; Merli, Francesco; Vallisa, Daniele; Baldini, Luca; Brugiatelli, Maura.

In: Cancer, Vol. 109, No. 10, 15.05.2007, p. 2077-2082.

Research output: Contribution to journalArticle

Sacchi, S, Pozzi, S, Marcheselli, L, Bari, A, Luminari, S, Angrilli, F, Merli, F, Vallisa, D, Baldini, L & Brugiatelli, M 2007, 'Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients', Cancer, vol. 109, no. 10, pp. 2077-2082. https://doi.org/10.1002/cncr.22649
Sacchi, Stefano ; Pozzi, Samantha ; Marcheselli, Luigi ; Bari, Alessia ; Luminari, Stefano ; Angrilli, Francesco ; Merli, Francesco ; Vallisa, Daniele ; Baldini, Luca ; Brugiatelli, Maura. / Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients. In: Cancer. 2007 ; Vol. 109, No. 10. pp. 2077-2082.
@article{e4c45da48f9848908d36d70b7386a2e3,
title = "Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients",
abstract = "BACKGROUND. It is unclear whether new treatment modalities have improved the survival of follicular lymphoma patients. Some data show that there has been no improvement in survival in the last 3 decades of the 20th century, whereas the results of recent retrospective studies suggest that evolving therapy has improved the outcome for follicular lymphoma patients. METHODS. To evaluate the impact of evolving therapies for follicular lymphoma, particularly the introduction of rituximab, the overall survival (OS), failure-free survival (FFS), and survival after recurrence (SAR) was analyzed in 438 advanced-stage follicular lymphoma patients enrolled in consecutive Gruppo Italiano Studio Linfomi (GISL) trials between 1988 and 2004. RESULTS. A stepwise improvement in FFS and a significant reduction in the hazard ratio was observed with succeeding studies. Cox regression analysis showed an improvement over time for OS, with a decline in the hazard ratio particularly evident in the group treated with rituximab. Furthermore, the SAR significantly improved in the group of patients treated with chemotherapy + rituximab. CONCLUSIONS. After adjusting for all parameters with an impact on FFS and OS, the results of multivariate analysis suggest that rituximab therapy has a favorable effect on the prognosis of follicular lymphoma. The data show that FFS and OS have significantly improved in advanced-stage follicular lymphoma patients treated on GISL protocols during the last 18 years. These improvements are related to evolving front-line and salvage therapies, particularly the introduction of rituximab in combination with chemotherapy.",
keywords = "Chemotherapy, Follicular lymphoma, Non-Hodgkin lymphoma, Rituximab, Treatment outcome",
author = "Stefano Sacchi and Samantha Pozzi and Luigi Marcheselli and Alessia Bari and Stefano Luminari and Francesco Angrilli and Francesco Merli and Daniele Vallisa and Luca Baldini and Maura Brugiatelli",
year = "2007",
month = "5",
day = "15",
doi = "10.1002/cncr.22649",
language = "English",
volume = "109",
pages = "2077--2082",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "10",

}

TY - JOUR

T1 - Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients

AU - Sacchi, Stefano

AU - Pozzi, Samantha

AU - Marcheselli, Luigi

AU - Bari, Alessia

AU - Luminari, Stefano

AU - Angrilli, Francesco

AU - Merli, Francesco

AU - Vallisa, Daniele

AU - Baldini, Luca

AU - Brugiatelli, Maura

PY - 2007/5/15

Y1 - 2007/5/15

N2 - BACKGROUND. It is unclear whether new treatment modalities have improved the survival of follicular lymphoma patients. Some data show that there has been no improvement in survival in the last 3 decades of the 20th century, whereas the results of recent retrospective studies suggest that evolving therapy has improved the outcome for follicular lymphoma patients. METHODS. To evaluate the impact of evolving therapies for follicular lymphoma, particularly the introduction of rituximab, the overall survival (OS), failure-free survival (FFS), and survival after recurrence (SAR) was analyzed in 438 advanced-stage follicular lymphoma patients enrolled in consecutive Gruppo Italiano Studio Linfomi (GISL) trials between 1988 and 2004. RESULTS. A stepwise improvement in FFS and a significant reduction in the hazard ratio was observed with succeeding studies. Cox regression analysis showed an improvement over time for OS, with a decline in the hazard ratio particularly evident in the group treated with rituximab. Furthermore, the SAR significantly improved in the group of patients treated with chemotherapy + rituximab. CONCLUSIONS. After adjusting for all parameters with an impact on FFS and OS, the results of multivariate analysis suggest that rituximab therapy has a favorable effect on the prognosis of follicular lymphoma. The data show that FFS and OS have significantly improved in advanced-stage follicular lymphoma patients treated on GISL protocols during the last 18 years. These improvements are related to evolving front-line and salvage therapies, particularly the introduction of rituximab in combination with chemotherapy.

AB - BACKGROUND. It is unclear whether new treatment modalities have improved the survival of follicular lymphoma patients. Some data show that there has been no improvement in survival in the last 3 decades of the 20th century, whereas the results of recent retrospective studies suggest that evolving therapy has improved the outcome for follicular lymphoma patients. METHODS. To evaluate the impact of evolving therapies for follicular lymphoma, particularly the introduction of rituximab, the overall survival (OS), failure-free survival (FFS), and survival after recurrence (SAR) was analyzed in 438 advanced-stage follicular lymphoma patients enrolled in consecutive Gruppo Italiano Studio Linfomi (GISL) trials between 1988 and 2004. RESULTS. A stepwise improvement in FFS and a significant reduction in the hazard ratio was observed with succeeding studies. Cox regression analysis showed an improvement over time for OS, with a decline in the hazard ratio particularly evident in the group treated with rituximab. Furthermore, the SAR significantly improved in the group of patients treated with chemotherapy + rituximab. CONCLUSIONS. After adjusting for all parameters with an impact on FFS and OS, the results of multivariate analysis suggest that rituximab therapy has a favorable effect on the prognosis of follicular lymphoma. The data show that FFS and OS have significantly improved in advanced-stage follicular lymphoma patients treated on GISL protocols during the last 18 years. These improvements are related to evolving front-line and salvage therapies, particularly the introduction of rituximab in combination with chemotherapy.

KW - Chemotherapy

KW - Follicular lymphoma

KW - Non-Hodgkin lymphoma

KW - Rituximab

KW - Treatment outcome

UR - http://www.scopus.com/inward/record.url?scp=34248398358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248398358&partnerID=8YFLogxK

U2 - 10.1002/cncr.22649

DO - 10.1002/cncr.22649

M3 - Article

C2 - 17394190

AN - SCOPUS:34248398358

VL - 109

SP - 2077

EP - 2082

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 10

ER -